Follow-Up in Inflammatory Breast Cancer

  • Flavia Morales-VasquezEmail author
  • Horacio Noe Lopez-Basave
  • Martin Granados-Garcia


There are no changes in the guidelines that cite different treatment in the case of the follow-up of inflammatory breast cancer (IBC) and locally advanced breast cancer. Thus, treatment should adhere to the already established guidelines for locally advanced cancer of metastatic cancer of the breast.

The result of treatment for IBC has improved impressively with the advent of multimodal treatment. Within a period of 20 years, with the introduction of anthracyclines, 5- and 10-year global survival (GS) rates of 40 and 30 % have been reported, respectively. The incorporation of taxanes has been associated with better complete pathological response (cPR) rates and improvement in survival indices. According to the National Cancer Institute’s Surveillance, Epidemiology and End Results (NCI SEER) database, between 1988 and 2001, mean 5-year survival was reported as 40 % for women with IBC against 87 % reported for all cases of breast cancer.

After recurrence, the majority of patients will die. Thus, IBC continues to be one of the most lethal forms of breast cancer.

In this chapter, our purpose is to define the term recurrence, to summarize the general recommendations, to describe the possible clinical condition, the risk factors, the treatment options, their complications, and finally, in the conclusions, to highlight the focus toward which this treatment should be oriented.


Breast Cancer Hormone Therapy Zoledronic Acid Aromatase Inhibitor Inflammatory Breast Cancer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Zucali R, Uslenghi C, Kenda R, Bonadonna G. Natural history and survival of inoperable breast cancer treated with radiotherapy and radiotherapy followed by radical mastectomy. Cancer. 1976;37(3):1422–31.PubMedCrossRefGoogle Scholar
  2. 2.
    Ueno NT, Buzdar AU, Singletary SE, Ames FC, McNeese MD, Holmes FA, Theriault RL, Strom EA, Wasaff BJ, Asmar L, Frye D, Hortobagyi GN. Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at MD Anderson Cancer Center. Cancer Chemother Pharmacol. 1997;40(4):321–9.PubMedCrossRefGoogle Scholar
  3. 3.
    Hortobagyi GN, de la Garza Salazar J, Pritchard K, Amadori D, Haidinger R, Hudis CA, Khaled H, Liu MC, Martin M, Namer M, O’Shaughnessy JA, Shen ZZ, Albain KS, ABREAST Investigators. The global breast cancer burden: variations in epidemiology and survival (review). Clin Breast Cancer. 2005;6(5):391–401.PubMedCrossRefGoogle Scholar
  4. 4.
    Yoshida T, Takei H, Kurosumi M, Ninomiya J, Ishikawa Y, Hayashi Y, Tozuka K, Oba H, Kawanowa K, Inoue K, Tabei T. True recurrences and new primary tumors have different clinical features in invasive breast cancer patients with ipsilateral breast tumor relapse after breast-conserving treatment. Breast J. 2010;16(2):127–33. Epub 2009 Dec 21.PubMedCrossRefGoogle Scholar
  5. 5.
    Huber KE, Carey LA, Wazer DE. Breast cancer molecular subtypes in patients with locally advanced disease: impact on prognosis, patterns of recurrence, and response to therapy (review). Semin Radiat Oncol. 2009;19(4):204–10.PubMedCrossRefGoogle Scholar
  6. 6.
    Segunda Revisión del Consenso Nacional sobre el diagnóstico y tratamiento del Cáncer mamario. Colima; 2005.Google Scholar
  7. 7.
    NCCN (National Comprehensive Cancer Network). NCCN practice guidelines in oncology: breast cancer. 2012. Available at: Mar 2012.
  8. 8.
    López-Guerrero JA, Llombart-Cussac A, Noguera R, Navarro S, Pellin A, Almenar S, Vázquez-Alvadalejo C, Llombart-Bosch A. HER2 amplification in recurrent breast cancer following breast-conserving therapy correlates with distant metastasis and poor survival. Int J Cancer. 2006;118(7):1743–9.PubMedCrossRefGoogle Scholar
  9. 9.
    Rhee J, Han SW, Oh DY, et al. The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer. BMC Cancer. 2008;8:307.PubMedCrossRefGoogle Scholar
  10. 10.
    Kamby C, Ejlertsen B, Andersen J, et al. The pattern of metastases in human breast cancer. Influence of systemic adjuvant therapy and impact on survival. Acta Oncol. 1988;27:715–9.PubMedCrossRefGoogle Scholar
  11. 11.
    Early Breast Cancer Trialists’ Collaborative Group. Effects of chemotherapy and hormonal therapy in breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet. 2005;365:1687–717.CrossRefGoogle Scholar
  12. 12.
    Giordano SH, Buzdar AU, Smith TL, et al. Is breast cancer survival improving? Cancer. 2004;100:44.PubMedCrossRefGoogle Scholar
  13. 13.
    Gennari A, Conte P, Rosso R, et al. Survival of metastatic breast carcinoma patients over a 20-year period. Cancer. 2005;104:1742.PubMedCrossRefGoogle Scholar
  14. 14.
    González-Angulo AM, Morales-Vásquez F, Hortobagyi GN. Overview of resistance to systemic therapy in patients with breast cancer (review). Adv Exp Med Biol. 2007;608:122.Google Scholar
  15. 15.
    Soules MR, Sherman S, Parrott E, Rebar R. Executive summary: stages of reproductive aging workshop (STRAW). Fertil Steril. 2001;76:874.PubMedCrossRefGoogle Scholar
  16. 16.
    Nabholtz JM, Buzdar A, Pollak M, et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast carcinoma is postmenopausal women: results of a North America multicenter randomized trial. J Clin Oncol. 2000;18:3758–67.PubMedGoogle Scholar
  17. 17.
    Bonaterre J, Thurlimann B, Robertson JFR, et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability Study. J Clin Oncol. 2000;18:3748–57.Google Scholar
  18. 18.
    Mouridsen H, Gersanovich M, Sun Y, et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol. 2003;21:2101–9.PubMedCrossRefGoogle Scholar
  19. 19.
    Lonning PE, Bajetta E, Murray R, et al. Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trials. J Clin Oncol. 2000;18:2234–44.PubMedGoogle Scholar
  20. 20.
    Watanabe T, Sano M, Ohno S, et al. Fulvestrant for the treatment of advanced breast cancer in postmenopausal women: a Japanese study. Anticancer Res. 2004;24:1275.PubMedGoogle Scholar
  21. 21.
    Howell A, Pippen J, Elledge RM, et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma. Cancer. 2005;104:236.PubMedCrossRefGoogle Scholar
  22. 22.
    Osborne CK, Pippen J, Jones SE, et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol. 2002;20:3386.PubMedCrossRefGoogle Scholar
  23. 23.
    Howell A, Robertson JF, Quaresma Albano J, et al. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol. 2002;20:3396.PubMedCrossRefGoogle Scholar
  24. 24.
    Ingle JN, Suman VJ, Rowland KM, et al. Fulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitor therapy: North Central Cancer Treatment Group Trial N0032. J Clin Oncol. 2006;24:1052.PubMedCrossRefGoogle Scholar
  25. 25.
    Chia S, Gradishar W, Mauriac L, et al. Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J Clin Oncol. 2008;26:1664.PubMedCrossRefGoogle Scholar
  26. 26.
    Johnston SJ, Cheung KL. Fulvestrant- a novel endocrine therapy for breast cancer (review). Curr Med Chem. 2010;17(10):902–14.PubMedCrossRefGoogle Scholar
  27. 27.
    Robertson JF, Llombart-Cussac A, Rolski J, Feltl D, Dewar J, Macpherson E, Lindemann J, Ellis MJ. Activity of fulvestrant 500 mg versus anastrozole 1mg as first-line treatment for advanced breast cancer: results from the FIRST study. J Clin Oncol. 2009;27(27):4530–5. Epub 2009 Aug 24.PubMedCrossRefGoogle Scholar
  28. 28.
    Johnston S, Pergram M, Press M, et al. Lapatinib combined with letrozole vs. letrozole alone for front line postmenopausal hormone receptor positive (HR+) metastatic breast cancer (MBC). J Clin Oncol. 2009;27:5538–46.PubMedCrossRefGoogle Scholar
  29. 29.
    Hortobagyi GN, Yap HY, Kau SW, et al. A comparative study of doxorubicin and epirubicin in patients with metastatic breast cancer. Am J Clin Oncol. 1989;12:57.PubMedCrossRefGoogle Scholar
  30. 30.
    Falkson G, Tormey DC, Carey P, et al. Long-term survival of patients treated with combination chemotherapy for metastatic breast cancer. Eur J Cancer. 1991;27:973.PubMedCrossRefGoogle Scholar
  31. 31.
    Hortobagyi GN, Bodey GP, Buzdar AU, et al. Evaluation of high-dose versus standard FAC chemotherapy for advanced breast cancer in protected environment units: a prospective randomized study. J Clin Oncol. 1987;5:354.PubMedGoogle Scholar
  32. 32.
    Conte PF, Guarneri V, Bruzzi P, et al. Concomitant versus sequential administration of epirubicin and paclitaxel as first-line therapy in metastatic breast carcinoma: results for the Gruppo Oncologico Nord Ovest randomized trial. Cancer. 2004;101:704.PubMedCrossRefGoogle Scholar
  33. 33.
    O’Shaughnessy J, et al. Superior survival with capecitabine plus docetaxel. Combination therapy in anthracycline-pretreatment patients with advanced breast cancer. Phase III trial result. J Clin Oncol. 2002;12:2812–23.CrossRefGoogle Scholar
  34. 34.
    Carrick S, Parker S, Wilcken N, et al. Single agent versus combination chemotherapy for metastatic breast cancer. Cochrane Database Syst Rev. 2005:CD003372.Google Scholar
  35. 35.
    Blum JL, Dieras V, Lo Russo PM, et al. Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer. 2001;92:1759.PubMedCrossRefGoogle Scholar
  36. 36.
    Fumoleau P, Largillier R, Clippe C, et al. Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. Eur J Cancer. 2004;40:536.PubMedCrossRefGoogle Scholar
  37. 37.
    Reichardt P, Von Minckwitz G, Thuss-Patience PC, et al. Multicenter phase II study of oral capecitabine (Xeloda )in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy. Ann Oncol. 2003;14:1227.PubMedCrossRefGoogle Scholar
  38. 38.
    Gennari A, D’amico M, Corradengo D. Extending the duration of first-line chemotherapy in metastatic breast cancer: a perspective review. Ther Adv Med Oncol. 2011;3(5):229–232. doi: 10.1177/1758834011413423 Google Scholar
  39. 39.
    O’Shaughnessy J, Twelves C, Aapro M. Treatment for anthracycline-pretreated metastatic breast cancer. (Review). Oncologist. 2002;7 Suppl 6:4–12.PubMedCrossRefGoogle Scholar
  40. 40.
    Schaller G, Fuchs I, Gonsch T, Weber J, Kleine-Tebbe A, Klare P, Hindenburg HJ, Lakner V, Hinke A, Bangemann N. Phase II study of capecitabine plus trastuzumab in human epidermal growth factor ­receptor 2 overexpressing metastatic breast cancer pretreated with anthracyclines or taxanes. J Clin Oncol. 2007;25(22):3246–50. Epub 2007 Jun 18.PubMedCrossRefGoogle Scholar
  41. 41.
    Burstein HJ, Harris LN, Marcom PK, Lambert-Falls R, Havlin K, Overmoyer B, Friedlander Jr RJ, Gargiulo J, Strenger R, Vogel CL, Ryan PD, Ellis MJ, Nunes RA, Bunnell CA, Campos SM, Hallor M, Gelman R, Winer EP. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol. 2003;21(15):2889–95.PubMedCrossRefGoogle Scholar
  42. 42.
    Thomas ES, Gómez HL, Li RK, Chung HC, Fein LE, Chan VF, Jassem J, Pivot XB, Klimovsky JV, de Mendoza FH, Xu B, Campone M, Lerzo GL, Peck RA, Mukhopadhyay P, Vahdat LT, Roché HH. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol. 2007;25(33):5210–7. Epub 2007 Oct 29.PubMedCrossRefGoogle Scholar
  43. 43.
    Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P, Hawkins M, O’Shaughnessy J. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol. 2005;23(31):7794–803. Epub 2005 Sep 19.PubMedCrossRefGoogle Scholar
  44. 44.
    Martín M, Ruiz A, Muñoz M, Balil A, García-Mata J, Calvo L, Carrasco E, Mahillo E, Casado A, García-Sáenz JA, Escudero MJ, Guillem V, Jara C, Ribelles N, Salas F, Soto C, Morales-Vásquez F, Rodríguez CA, Adrover E, Mel JR, Spanish Breast Cancer Research Group (GEICAM) trial. Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial. Lancet Oncol. 2007;8(3):219–25.PubMedCrossRefGoogle Scholar
  45. 45.
    Coleman RE. Bisphosphonates in breast cancer. Ann Oncol. 2005;16:687–95.PubMedCrossRefGoogle Scholar
  46. 46.
    Winter MC, Coleman RE. Bisphosphonates in breast cancer: teaching an old dog new tricks. Curr Opin Oncol. 2009;21:499–506.PubMedCrossRefGoogle Scholar
  47. 47.
    Coleman WY. Meta-analysis of clodronate and breast cancer survival. Br J Cancer. 2007;96:1796–801.CrossRefGoogle Scholar
  48. 48.
    Coleman RE. Adjuvant bisphosphonates in breast cancer: Are we witnessing the emergence of a new tHER 2apeutic strategy? Eur J Cancer. 2009. doi: 10.1016/j.
  49. 49.
    Eidtmann H, Bundred NJ, DeBoer R. The effect of zoledronic acid on aromatase inhibitor associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36 months follow-up of ZO-FAST. Cancer Res. 2008;69(Suppl 2). Abstract 44. San Antonio breast cancer symposium.Google Scholar
  50. 50.
    Gnant M, Mlineritsch B, Schippinger W, et al. Endocrine tHER 2apy plus zoledronic acid in premenopausal breast cancer. N Engl J Med. 2009;360(7):679–91.PubMedCrossRefGoogle Scholar
  51. 51.
    Pavlakis N, Schmidt R, Stockler M. Bisphosphonates for breast cancer. Cochrane Database Syst Rev 2005;(3):CD003474. Epub 2005 Jul 20.Google Scholar
  52. 52.
    Rosen LS, Gordon DH, et al. Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer. 2004;100:36–43.PubMedCrossRefGoogle Scholar
  53. 53.
    NCCN Task Force Report. Bone health in cancer care. J Natl Compr Canc Netw. 2009;7 Suppl 3:1–32.Google Scholar

Copyright information

© Springer-Verlag London 2013

Authors and Affiliations

  • Flavia Morales-Vasquez
    • 1
    Email author
  • Horacio Noe Lopez-Basave
    • 2
  • Martin Granados-Garcia
    • 2
  1. 1.Department of Medical OncologyInstituto Nacional de Cancerologia-MexicoTlalpan, Mexico CityMexico
  2. 2.Department of Oncological SurgeryInstituto Nacional de Cancerologia-MexicoMexico CityMexico

Personalised recommendations